Sutro Biopharma, Inc.
STRONasdaqCIK 1382101HealthcareFiscal year ends Dec 31
Reports and events: 136 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-05-1508:05 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-021976 |
| 2023-05-1508:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-021973 |
| 2023-04-2816:04 ET | DEF 14A | Proxy statementPeriod 2023-06-08 | 0000950170-23-015762 |
| 2023-04-2716:31 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-015323 |
| 2023-04-1416:06 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-012879 |
| 2023-03-3016:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-010978 |
| 2023-03-3016:31 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-010976 |
| 2023-02-2416:06 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-23-004373 |
| 2023-01-0917:15 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-000528 |
| 2022-12-2016:07 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-22-026823 |
| 2022-11-0816:33 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-023279 |
| 2022-11-0816:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-023274 |
| 2022-10-2407:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-22-019872 |
| 2022-08-0816:42 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-015584 |
| 2022-08-0816:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-015573 |
| 2022-07-2616:02 ET | 8-K | 8.01 Other events | 0000950170-22-013078 |
| 2022-06-2819:31 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-22-012215 |
| 2022-06-1607:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-22-011712 |
| 2022-06-0717:00 ET | 8-K | 5.07 Shareholder vote results | 0000950170-22-011282 |
| 2022-05-0916:34 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008531 |
| 2022-05-0916:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-008525 |
| 2022-04-2519:55 ET | DEF 14A | Proxy statementPeriod 2022-06-06 | 0000950170-22-006031 |
| 2022-04-2007:00 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-22-005825 |
| 2022-02-2816:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-002316 |
| 2022-02-2816:32 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-002312 |
| 2022-01-1007:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-22-000168 |
| 2022-01-0517:27 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-22-000081 |
| 2021-12-2707:00 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-21-005353 |
| 2021-11-1707:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-057374 |
| 2021-11-1007:03 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001564590-21-055917 |
| 2021-11-1018:15 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001564590-21-055843 |
| 2021-10-1207:00 ET | 8-K | 1.01 Entry into a material agreement | 0001564590-21-050583 |
| 2021-09-3007:00 ET | 8-K | 8.01 Other events | 0001564590-21-049553 |
| 2021-08-0907:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-042330 |
| 2021-08-0917:36 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-042217 |
| 2021-06-1717:29 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001564590-21-033400 |
| 2021-06-0407:00 ET | 8-K | 5.07 Shareholder vote results | 0001564590-21-031670 |
| 2021-05-1917:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001564590-21-028892 |
| 2021-05-0707:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-025294 |
| 2021-05-0718:01 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-025155 |
| 2021-04-2917:00 ET | DEF 14A | Proxy statementPeriod 2021-06-03 | 0001564590-21-022043 |
| 2021-04-1507:00 ET | 8-K | 8.01 Other events | 0001564590-21-018899 |
| 2021-03-1807:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-014003 |
| 2021-03-1818:52 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-013945 |
| 2020-12-0916:38 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001564590-20-056578 |
| 2020-12-0715:45 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001564590-20-056289 |
| 2020-12-0419:38 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001564590-20-056109 |
| 2020-12-0107:09 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-20-055673 |
| 2020-11-0507:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-050851 |
| 2020-11-0521:31 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001564590-20-050755 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.